ATE53176T1 - Pharmazeutische zusammensetzung mit verzoegerter abgabe. - Google Patents

Pharmazeutische zusammensetzung mit verzoegerter abgabe.

Info

Publication number
ATE53176T1
ATE53176T1 AT84301954T AT84301954T ATE53176T1 AT E53176 T1 ATE53176 T1 AT E53176T1 AT 84301954 T AT84301954 T AT 84301954T AT 84301954 T AT84301954 T AT 84301954T AT E53176 T1 ATE53176 T1 AT E53176T1
Authority
AT
Austria
Prior art keywords
theophylline
total
hours
pharmaceutical composition
delayed release
Prior art date
Application number
AT84301954T
Other languages
English (en)
Inventor
Donald Eugene Panoz
Edward James Geoghegan
Original Assignee
Elan Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp Plc filed Critical Elan Corp Plc
Application granted granted Critical
Publication of ATE53176T1 publication Critical patent/ATE53176T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT84301954T 1983-04-06 1984-03-22 Pharmazeutische zusammensetzung mit verzoegerter abgabe. ATE53176T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE789/83A IE55745B1 (en) 1983-04-06 1983-04-06 Sustained absorption pharmaceutical composition
EP84301954A EP0122077B1 (de) 1983-04-06 1984-03-22 Pharmazeutische Zusammensetzung mit verzögerter Abgabe

Publications (1)

Publication Number Publication Date
ATE53176T1 true ATE53176T1 (de) 1990-06-15

Family

ID=11018164

Family Applications (1)

Application Number Title Priority Date Filing Date
AT84301954T ATE53176T1 (de) 1983-04-06 1984-03-22 Pharmazeutische zusammensetzung mit verzoegerter abgabe.

Country Status (9)

Country Link
US (2) US4663150A (de)
EP (1) EP0122077B1 (de)
JP (1) JPS59219219A (de)
AT (1) ATE53176T1 (de)
BE (1) BE899293A (de)
CH (1) CH660688B (de)
DE (1) DE3482374D1 (de)
IE (1) IE55745B1 (de)
PH (1) PH18904A (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
IE58246B1 (en) * 1984-12-21 1993-08-11 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation
GB2170104A (en) * 1985-01-30 1986-07-30 Warner Lambert Co Coated pharmaceutical dosage forms
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US4826688A (en) * 1985-11-13 1989-05-02 501 Elan Corporation PLC. Controlled absorption pharmaceutical formulation
US5026709A (en) * 1986-04-07 1991-06-25 Rorer Pharmaceutical Corporation Method for the preparation of a theophylline sustained release pharmaceutical composition and the composition prepared thereby
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
US5286494A (en) * 1986-07-02 1994-02-15 Schering Aktiengesellschaft Medicinal agents with sustained action
GB8628728D0 (en) * 1986-12-02 1987-01-07 Euro Celtique Sa Spheroids
IL84599A0 (en) * 1986-12-09 1988-04-29 Byk Gulden Lomberg Chem Fab Pharmaceutical composition containing urapidil and process for the preparation thereof
US4789549A (en) * 1987-03-09 1988-12-06 Warner-Lambert Company Sustained release dosage forms
CA1323833C (en) * 1987-04-28 1993-11-02 Yatindra M. Joshi Pharmaceutical compositions in the form of beadlets and method
US4808413A (en) * 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
US4786509A (en) * 1987-05-18 1988-11-22 Schering Corporation Dry sustained release theophylline oral formulation
PT88776B (pt) * 1987-10-16 1992-12-31 Elan Corp Limites Processo para a preparacao de formulacoes de diltiazem de absorcao controlada
IE64726B1 (en) * 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US5296236A (en) * 1988-09-16 1994-03-22 Recordati S.A., Chemical And Pharmaceutical Company Controlled release therapeutic system for a liquid pharmaceutical formulations
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
DE3929864A1 (de) * 1989-09-08 1991-03-14 Nordmark Arzneimittel Gmbh Verfahren zur herstellung von theophyllin-pellets
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
US5162110A (en) * 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
JP3426230B2 (ja) * 1991-05-20 2003-07-14 アベンティス・ファーマスーティカルズ・インコーポレイテッド 複数層の制御放出処方剤
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
SE9202250D0 (sv) * 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation
US5744164A (en) * 1994-12-16 1998-04-28 Nestec S.A. Sustained release microparticulate caffeine formulation
US5766623A (en) * 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
US20030215507A1 (en) * 1996-03-25 2003-11-20 Wyeth Extended release formulation
US20060068001A1 (en) * 1996-03-25 2006-03-30 Wyeth Extended release formulation
FR2758461A1 (fr) * 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
DE19845358A1 (de) * 1998-10-02 2000-04-06 Roehm Gmbh Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
EP1536774A1 (de) * 2002-09-04 2005-06-08 Ranbaxy Laboratories Limited Dosierformen mit maskiertem geschmack und verfahren zu ihrer herstellung
GB0227948D0 (en) * 2002-11-29 2003-01-08 Cipla Ltd Pharmaceutical combinations comprising b-2 adrenoreceptor agonists and xanthines
US9107804B2 (en) * 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
DE10353196A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
EP1753405A4 (de) * 2004-06-10 2008-09-17 Glatt Air Tech Inc Pharmazeutische formulierung mit kontrollierter freisetzung
JP2008534530A (ja) * 2005-03-29 2008-08-28 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング 活性成分放出に関して調節作用を有する物質を有するペレットを含有している多粒子薬剤形
EP1743638A1 (de) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Pharmazeutische Formulierungen von substituierten Pyrazolinderivaten
AU2006269944A1 (en) * 2005-07-19 2007-01-25 Inverseon, Inc. Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases
CN103211779B (zh) * 2006-01-27 2016-03-16 阿代尔制药股份有限公司 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
ES2533563T5 (es) * 2006-01-27 2018-07-24 Adare Pharmaceuticals, Inc. Sistemas de suministro de fármacos que comprenden fármacos débilmente básicos y ácidos orgánicos
CN101484147B (zh) * 2006-08-18 2015-07-08 赢创罗姆有限责任公司 对于具有水中良好溶解性的活性成分具有受控的活性成分释放性的药物组合物
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US8992898B2 (en) 2010-04-17 2015-03-31 Shannon Elizabeth Klingman Antiperspirants and deodorants
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
PL3628311T3 (pl) * 2018-09-27 2021-07-05 Inibsa Ginecologia, S.A. Sposób wytwarzania doustnej wielojednostkowej postaci dawkowanej bursztynianu doksylaminy i chlorowodorku pirydoksyny o zmodyfikowanym uwalnianiu
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2853420A (en) * 1956-01-25 1958-09-23 Lowey Hans Ethyl cellulose coatings for shaped medicinal preparations
US3081233A (en) * 1960-08-08 1963-03-12 Upjohn Co Enteric-coated pilules
NL122039C (de) * 1960-10-20
NL297088A (de) * 1961-01-31
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
NL297631A (de) * 1963-06-03
US3949068A (en) * 1964-02-20 1976-04-06 University Of Alabama In Birmingham Medical And Educational Foundation Pharmaceutical compositions
US3400185A (en) * 1965-04-08 1968-09-03 Bristol Myers Co Agglomeration of smaller pharmaceutical particles into larger microspherules and enteic-coating thereof
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
DE2343218C2 (de) * 1973-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Furosemid enthaltende Pellets
US3906087A (en) * 1973-09-10 1975-09-16 Union Corp Sustained release of methantheline
US4085214A (en) * 1976-10-18 1978-04-18 Interx Research Corporation Stable pro-drug forms of theophylline
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4248858A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
JPS56122311A (en) * 1980-02-29 1981-09-25 Eisai Co Ltd Lasting theophylline pharmaceutical composition
NZ196349A (en) * 1980-03-07 1984-08-24 Interx Research Corp Enhancement of absorption rate of orally administered polar bioactive agents
DE3127237A1 (de) * 1981-07-10 1983-01-20 Hoechst Ag, 6000 Frankfurt Magenvertraegliche arzneiformen von xanthinderivaten und verfahren zu ihrer herstellung
DE3278491D1 (en) * 1981-07-15 1988-06-23 Key Pharma Sustained release theophyline
IT1153487B (it) * 1982-04-15 1987-01-14 Prophin Lab Spa Prodotti farmaceutici in forma-ritardo e procedimento per ottenerli
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
US4710384A (en) * 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules

Also Published As

Publication number Publication date
CH660688B (de) 1987-06-15
JPH0466207B2 (de) 1992-10-22
US4820521A (en) 1989-04-11
US4663150A (en) 1987-05-05
EP0122077B1 (de) 1990-05-30
PH18904A (en) 1985-10-30
EP0122077A2 (de) 1984-10-17
EP0122077A3 (en) 1985-09-11
IE55745B1 (en) 1991-01-02
JPS59219219A (ja) 1984-12-10
DE3482374D1 (de) 1990-07-05
BE899293A (fr) 1984-07-16

Similar Documents

Publication Publication Date Title
ATE53176T1 (de) Pharmazeutische zusammensetzung mit verzoegerter abgabe.
ATE66813T1 (de) Arzneimittel-formulierung.
ATE43497T1 (de) Pharmazeutische formulierung mit gesteuerter absorption.
US4767628B1 (de)
DE3773468D1 (de) Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung.
ATE107857T1 (de) Zusammensetzung mit kontrollierter freisetzung von dihydrocodein.
DE69000881D1 (de) 2-propylvaleriansaeure enthaltende arzneizubereitung mit verzoegerter wirkstofffreigabe.
AR065072A2 (es) Una formulacion medicamentosa de pellet de difusion controlada que tiene liberacion controlada de un compuesto activo
DE69133623D1 (de) Haltende neue pharmazeutische formulierungen sowie verfahren zu deren herstellung
DE58903856D1 (de) Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung.
ES2194832T3 (es) Formulaciones de ditiazem con absorcion controlada.
IT8220758A1 (it) Prodotti farmaceutici in forma-ritardo e procedimento per ottenerli
ZA884622B (en) Pharmaceutical compositions in the form of pellets with enzymatically controlled release of the pharmaceutical,substance
AR230425A1 (es) Procedimiento para la preparacion de derivados de 1-(5,6,7,8-tetrahidronaftiloxi)-2-hidroxi-3-amino-propano y 4-(3-amino-2-hidroxi-propoxi)-6,7,8,9-tetrahidro-5h-benzocicloheptano activos sobre el sistema cardiovascular